Two different immunotherapy strategies will be evaluated in our research, one based on the use of anti-tumor Immunotoxins (ITs) (PASSIVE IMMUNOTHERAPY) and the second based on the use of genetically engineered cells (ACTIVE IMMUNOTHERAPY).
We expect that our efforts would enable us to set up in vitro and in vivo models to test separately and in combination the efficacy of these two treatment modalities, particularly for the management of bone metastases and of the minimal residual disease.